Currently accepted at: Journal of Medical Internet Research
Date Submitted: Jul 7, 2026
Date Accepted: Nov 20, 2026
This paper has been accepted and is currently in production.
It will appear shortly on 10.2196/106447
The final accepted version (not copyedited yet) is in this tab.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Evaluation of Digital Therapeutics: Tutorial on Adaptive Design Methods
ABSTRACT
Software-based digital therapeutics (DTx) are increasingly integrated into routine health care. To enable early access for patients to innovative interventions, there are options for early market access/provisional reimbursement of DTx within regulatory frameworks, such as the German Digital Health Applications (DiGA) fast-track pathway, implemented by the Federal Institute for Drugs and Medical Devices (BfArM). They highlight both the opportunities and challenges of generating robust evidence under conditions of early market access (provisional registration for reimbursement). In particular, the widespread separation of pilot studies (for provisional registration) and confirmatory studies (for permanent registration) in such frameworks can lead to duplicate data collection, inefficient resource use, and practical difficulties in meeting evidence requirements within constrained timelines. This tutorial provides an accessible introduction to adaptive clinical trial designs and demonstrates their application to the evaluation of DTx in registration studies such as the German fast-track pathway. The focus is on the conditional-error-function approach. We explain how this approach enables integrating the pilot and confirmatory stages into a single, coherent trial design while maintaining strict control of type I error despite possible design modifications at interim analyses. This includes sample size recalculations. When deciding to conduct a single two-stage adaptive study, the pilot-stage data can be used for provisional registration, and the data from both stages (pilot and confirmatory) can be used for permanent registration. In addition, the tutorial addresses common complexities in DTx evaluation, including multiple relevant endpoints and heterogeneity across patient subgroups. We introduce methods for handling multiplicity, such as Bonferroni adjustments and the closed testing principle. We illustrate how these principles can be incorporated into adaptive designs to support flexible endpoint or subgroup selection after some data have been collected, without compromising statistical validity. Practical examples, inspired by real-world registration studies in the DiGA context, demonstrate how adaptive designs can improve efficiency by reducing overall sample size requirements, shortening study timelines, and enabling a more informative use of pilot-stage data. Beyond the German setting, we discuss the broader applicability of adaptive designs to international DTx evaluation frameworks. Many of these frameworks face similar challenges in balancing timely access to innovation with the need for robust confirmatory evidence. By translating established statistical methodologies into a form accessible to digital health researchers, developers, and regulators, this tutorial aims to support the adoption of more efficient and flexible evaluation strategies. In conclusion, adaptive trial designs represent a powerful, statistically valid, and practical approach for improving the evaluation of DTx.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.